Veterinary pathology

Strand Therapeutics Appoints Dr. Prashant Nambiar as Senior Vice President, Research and Translational Development

Retrieved on: 
Tuesday, February 8, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, U.S. Department of Defense Strategy for Operating in Cyberspace, Risk assessment, Business, Senior, Multimedia, Pfizer, Massachusetts Institute of Technology, Doctor of Philosophy, Bluebird bio, Research, Toxicity, Veterinary pathology, IND, Therapy, Pharmacology, Leadership, Gene editing, Technology, University, Safety, University of Connecticut Health Center, RNA transfection, Synthetic biology, DVM, Pathology, MIT Sloan School of Management, Drug development, MIT, Prashant, Drug discovery, MBA, Pharmaceutical industry, Cancer, Toxicology

Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, today announced that Prashant Nambiar, DVM, PhD, MBA has been appointed Senior Vice President, Research and Translational Development.

Key Points: 
  • Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, today announced that Prashant Nambiar, DVM, PhD, MBA has been appointed Senior Vice President, Research and Translational Development.
  • With almost two decades in the pharmaceutical and biotechnology industry, Dr. Nambiar brings significant experience in drug discovery, pharmacology and translational development across different therapeutic areas and modalities.
  • His experience in drug development and strategic operations will allow us to advance our platform technology, expand our pipeline, and build out our research and translational development groups.
  • Strand Therapeutics is an emerging biopharmaceutical company poised at the forefront of mRNA therapeutics and synthetic biology.

FDA Announces New Resource for Veterinarians and Pet Owners Interested in Clinical Field Studies of Animal Cells, Tissues, and Cell- and Tissue-Based Products

Retrieved on: 
Monday, February 8, 2021
Health, Articles, Food and Drug Administration, United States Public Health Service, Veterinary physician, Clinical trial, Veterinary medicine, Veterinary pathology

Today, the U.S. Food and Drug Administration is announcing a listing of clinical field studies that are investigating Animal Cells, Tissues, and Cell- and Tissue-Based Products (ACTPs) in veterinary patients.

Key Points: 
  • Today, the U.S. Food and Drug Administration is announcing a listing of clinical field studies that are investigating Animal Cells, Tissues, and Cell- and Tissue-Based Products (ACTPs) in veterinary patients.
  • The webpage provides animal owners, veterinarians, researchers and the public with information on clinical field studies that are being investigated for the use of ACTPs in veterinary patients.
  • Connecting interested pet owners and their veterinary teams with relevant clinical studies also helps sponsors in generating data toward potential FDA approval.
  • At the time of listing, the information is intended to disclose clinical field studies in support of product development and FDA approval.

The global digital pathology market is projected to reach USD 1,054 million by 2025 from USD 553 million in 2020, at a CAGR of 13.8%

Retrieved on: 
Tuesday, November 3, 2020
Microscopy, Pathology, Digital pathology, Biology, Veterinary pathology, Life sciences, Articles

The global digital pathology market is projected to reach USD 1,054 million by 2025 from USD 553 million in 2020, at a CAGR of 13.8% during the forecast period.

Key Points: 
  • The global digital pathology market is projected to reach USD 1,054 million by 2025 from USD 553 million in 2020, at a CAGR of 13.8% during the forecast period.
  • On the basis of product, the digital pathology market is segmented into scanners, software, communication systems, and storage systems.The scanners segment accounted for the largest share of the digital pathology market in 2019.
  • On the basis of type, the global digital pathology market is segmented into human and veterinary pathology.The human pathology segment accounted for the largest share of the digital pathology market in 2019.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the digital pathology market.

Global Anatomic Pathology Market Analysis 2020-2025 - by Product & Service, Consumables, Application, End User and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 25, 2020
Professional services, Consulting, Branches of biology, Biology, Anatomical pathology, Pathology, Medicine, Medical laboratory, Histopathology, Veterinary pathology

The "Anatomic Pathology Market by Product & Service (Instruments (Tissue Processors, Microtome), Consumables (Antibodies), Histopathology), Application (Disease Diagnosis (Cancer (Gastrointestinal, Lung)), End User, Region - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anatomic Pathology Market by Product & Service (Instruments (Tissue Processors, Microtome), Consumables (Antibodies), Histopathology), Application (Disease Diagnosis (Cancer (Gastrointestinal, Lung)), End User, Region - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.
  • Disease diagnosis segment accounted for the larger share of the anatomic pathology market, by application, in 2019.
  • Based on end-users, the anatomic pathology market is segmented into clinical laboratories, hospital laboratories, and other end users.
  • Geographically, the anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World.

Precision Pathology Services and bioAffinity Technologies Announce Initiation of CLIA Validation for Non-Invasive Early Lung Cancer Test

Retrieved on: 
Wednesday, August 12, 2020
Other Health, Radiology, Other Science, Research, Oncology, Medical devices, Hardware, Hospitals, Electronic design automation, Stem cells, Science, Technology, Clinical trials, Managed care, General Health, FDA, Biotechnology, Health, Pathology, Clinical pathology, Articles, Biology, Clinical Laboratory Improvement Amendments, Health, Anatomical pathology, Veterinary pathology

bioAffinity Technologies , a privately held biotech company advancing cutting-edge cancer diagnostics, and Precision Pathology Services , a CAP/CLIA-certified anatomic and clinical pathology laboratory, announced initiation of CLIA validation for CyPath Lung, a non-invasive flow cytometric test for early-stage lung cancer.

Key Points: 
  • bioAffinity Technologies , a privately held biotech company advancing cutting-edge cancer diagnostics, and Precision Pathology Services , a CAP/CLIA-certified anatomic and clinical pathology laboratory, announced initiation of CLIA validation for CyPath Lung, a non-invasive flow cytometric test for early-stage lung cancer.
  • Precision Pathology has licensed bioAffinitys intellectual property for development of CyPath Lung as a laboratory developed test (LDT).
  • CyPath Lung is a flow cytometric test to aid in the diagnosis of lung cancer.
  • The board-certified pathologists practicing at Precision Pathology Services and Village Oaks Pathology Services, PA, have provided anatomic and clinical pathology services for patients and their physicians since 1986.

The Global Anatomic Pathology Testing Market is expected to grow from USD 33,980.03 Million in 2019 to USD 46,015.27 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.18%

Retrieved on: 
Monday, July 27, 2020
Pathology, Anatomical pathology, Coronavirus disease, Biology, Medical specialties, Academic disciplines, Veterinary pathology

On the basis of Application, the Anatomic Pathology Testing Market is studied across Disease Diagnosis and Drug Discovery & Development.

Key Points: 
  • On the basis of Application, the Anatomic Pathology Testing Market is studied across Disease Diagnosis and Drug Discovery & Development.
  • On the basis of Geography, the Anatomic Pathology Testing Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Anatomic Pathology Testing Market during the forecast period?
  • What are the modes and strategic moves considered suitable for entering the Global Anatomic Pathology Testing Market?

The Global Anatomic Pathology Market is expected to grow from USD 26,189.81 Million in 2019 to USD 38,258.73 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.52%

Retrieved on: 
Monday, July 27, 2020
Anatomical pathology, Pathology, Medical laboratory, Natural sciences, Veterinary pathology

On the basis of Appl?cati?n, the Anatomic Pathology Market is studied across Disease Diagnostics and Medical Research.

Key Points: 
  • On the basis of Appl?cati?n, the Anatomic Pathology Market is studied across Disease Diagnostics and Medical Research.
  • On the basis of End User, the Anatomic Pathology Market is studied across Clinical Laboratories and Hospital Laboratories.
  • On the basis of Geography, the Anatomic Pathology Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the modes and strategic moves considered suitable for entering the Global Anatomic Pathology Market?

Global Digital Pathology Market Assessment 2020-2025 - Market Expected to Cross $1.1 Trillion by 2025, with North America Growing at the Highest Rate

Retrieved on: 
Friday, July 10, 2020
Microscopy, Pathology, Digital pathology, Veterinary pathology, Biology, Academic disciplines, Life sciences

However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent.

Key Points: 
  • However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent.
  • By type, the human pathology segment accounted for the largest share of the digital pathology market in 2019.
  • On the basis of type, the global digital pathology market is segmented into human and veterinary pathology.
  • The human pathology segment accounted for the largest share of the digital pathology market in 2019.

Global Digital Pathology Market (2020 to 2025) - High Scope of Growth in Emerging Economies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 31, 2020
Technology, Science, Other Science, Other Technology, Microscopy, Pathology, Digital pathology, Veterinary pathology, Biology, Academic disciplines, Life sciences

However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent.

Key Points: 
  • However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent.
  • By type, the human pathology segment accounted for the largest share of the digital pathology market in 2019.
  • On the basis of type, the global digital pathology market is segmented into human and veterinary pathology.
  • The human pathology segment accounted for the largest share of the digital pathology market in 2019.

AnPac Bio Receives Accreditation for United States Laboratory from College of American Pathologists

College of American Pathologists, Medicine, Health, Branches of biology, Medical laboratory, Pathology, Veterinary pathology, Royal College of Pathologists of Australasia

Anpac Bio is proud to have received this accreditation, said Chris Yu, Chairman and CEO of Anpac Bio.

Key Points: 
  • Anpac Bio is proud to have received this accreditation, said Chris Yu, Chairman and CEO of Anpac Bio.
  • The College of American Pathologists (CAP) is the gold standard in medical laboratory accreditation.
  • Through this rigorous inspection process, CAP has certified that Anpac Bio is meeting the highest standards in quality patient care.
  • As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.